Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature

Case Reports in Oncology

Volumn 5, Issue 2, 2012, Pages 354-358

  Salazar, Ramn ^a   Cuadra, Carmen ^a   Gil Martn, Marta ^a   Vandermeeren, Andrea ^b   Alfaro, Vicente ^b   Coronado, Cinthya ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b PHARMAMAR S A   (Spain)

Author keywords

Chemotherapy; Esophageal cancer; Irvalec; Large cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DEHYDRODIDEMNIN B; DOCETAXEL; ELISIDEPSIN; FLUOROURACIL;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; MYALGIA; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE;

EID: 84866845103     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000341104     Document Type: Review

References (15)

1. Ilson DH: Esophageal cancer chemotherapy: Recent advances. Gastrointest Cancer Res 2008;2:85-92.
2. Coronado C, Galmarini CM, Alfaro V, Yovine A: Elisidepsin. Drugs Fut 2010;35:287-296.
3. Walker AM: Identification of esophageal cancer in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2011;20:1159-1167.
4. Trivers KF, Sabatino SA, Stewart SL: Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 2008;123:1422-1428.
5. Schlansky B, Dimarino AJ Jr, Loren D, Infantolino A, Kowalski T, Cohen S: A survey of oesophageal cancer: Pathology, stage and clinical presentation. Aliment Pharmacol Ther 2006;23:587-593.
6. Kok TC, Nooter K, Tjong AHSP, Smits HL, Ter Schegget JT: No evidence of known types of human papillomavirus in squamous cell cancer of the oesophagus in a low-risk area. Rotterdam Oesophageal Tumour Study Group. Eur J Cancer 1997;33:1865-1868.
7. Safieddine N, Xu W, Quadri SM, Knox JJ, Hornby J, Sulman J, et al: Health-related quality of life in esophageal cancer: Effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J Thorac Cardiovasc Surg 2009;137:36-42.
8. Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, et al: Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28(suppl 1):S152-S161.
9. Muijs CT, Beukema JC, Mul VE, Plukker JT, Sijtsema NM, Langendijk JA: External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma. Radiother Oncol 2012;102:303-308.
10. Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H, et al: Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: A case-control study. BMC Cancer 2012;12:70
11. Stahl M, Budach W, Meyer HJ, Cervantes A: Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v46-v49.
12. Nemoto H, Takeuchi S, Nagasaki H, Yoshizawa Y, Kikuchi H, Yagi H, et al: Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy. Gan To Kagaku Ryoho 2003;30:263-267.
13. Shimizu K, Takiyama W, Mandai K, Tanada M, Kawabuchi Y, Heike Y: Undifferentiated carcinoma with lymphoid infiltration of the esophagus: A case report. Jpn J Clin Oncol 1999;29:494-497.
14. Mori S, Tagaya N, Hamada K, Nakagawa A, Sawada T, Honma K, et al: Undifferentiated carcinoma of the esophagus with rapid growth of lymph node. A case report and review of the literature. Tumori 2008;94:411-415.
15. Shin S, Yoshinori H, Wataru A, Masanobu H, Taku Y, Yuki H, et al: Undifferentiated carcinoma of the esophagus (non-small cell type) - a case report and review of the literature in Japan. Jpn J Gastroenterol Surg 2005;38:19-24.